Engineering T cell memory for antitumor immunity

Aladdin M Bhuiyan; Michael Dougan

doi:10.1016/j.tips.2021.11.003

Engineering T cell memory for antitumor immunity

Trends Pharmacol Sci. 2022 Jan;43(1):1-3. doi: 10.1016/j.tips.2021.11.003. Epub 2021 Nov 13.

Authors

Aladdin M Bhuiyan¹, Michael Dougan²

Affiliations

¹ Albert Einstein College of Medicine, Bronx, NY, USA.
² Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: mldougan@partners.org.

PMID: 34785086
DOI: 10.1016/j.tips.2021.11.003

Abstract

Cancer therapy with the T cell growth factor interleukin (IL)-2 is limited by low response rates and toxicity. Multiple protein engineering strategies have attempted to improve IL-2 therapy, typically through enhanced IL-2 receptor (IL-2R) binding. Intriguingly, Mo et al. show that an IL-2R partial agonist may dramatically improve IL-2 responses by altering T cell differentiation.

Keywords: CAR T cell; IL-2 mimetic; IL-2 receptor; T cell exhaustion.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunologic Memory*
Immunotherapy
Interleukin-2* / metabolism
Neoplasms* / immunology
Receptors, Interleukin-2* / metabolism
T-Lymphocytes* / immunology

Substances

Interleukin-2
Receptors, Interleukin-2

Abstract

Publication types

MeSH terms

Substances

Grants and funding